Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Italian Journal of Dermatology and Venereology 2021 August;156(4) > Italian Journal of Dermatology and Venereology 2021 August;156(4):434-9



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


ORIGINAL ARTICLE   Free accessfree

Italian Journal of Dermatology and Venereology 2021 August;156(4):434-9

DOI: 10.23736/S2784-8671.20.06623-7


lingua: Inglese

Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis

Annunziata DATTOLA 1 , Laura VOLLONO 1, Maria V. CANNIZZARO1, Raffaele D. CAPOSIENA CARO 1, Sara MAZZILLI 1, Gennaro MELINO 2, Eleonora CANDI 2, Elena CAMPIONE 1, Luca BIANCHI 1

1 Department of Dermatology, Tor Vergata University, Rome, Italy; 2 Department of Experimental Medicine, Tor Vergata University, Rome, Italy

BACKGROUND: The efficacy and safety of certolizumab pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more antitumor necrosis factor (TNF)-α and/or anti-interleukin (IL) agents.
METHODS: We reported results in 50 patients affected by both mild psoriasis (PsO) and psoriatic arthritis (PsA). Primary endpoint was a reduction from baseline at week 52 of Disease Activity Score (DAS44-ESR) in both groups of patients. Secondary endpoints were a reduction from baseline at week 52 of Psoriasis Area Severity Index (PASI), Visual Analog Scale for Pain (PAIN VAS), ESR, CRP, and Dermatology Life Quality Index (DLQI).
RESULTS: We observed a statistically significant improvement of both cutaneous and rheumatic disease in all patients, with a consistent reduction of DAS44-ESR, PASI, and PAIN VAS from baseline to week 52. DAS44-ESR decreased from 3.9 at BL to 1.5 at W52 (Group 1), and from 3.8 to 1.7 at W52 (Group 2). Mean PASI Score decreased from 3.2 at baseline (BL) to 0.4 at W52 (Group 1), and from 5.4 to 0.7 at W52 (Group 2). Mean PAIN-VAS decreased from a value of 73.5 at BL to 2.5 at W52 (Group 1), and from a value of 62.4 at BL to 9.2 at W52 (Group 2). We also found a reduction in ESR, CRP and DLQI values for each time point.
CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents.

KEY WORDS: Psoriasis; Certolizumab pegol; Dermatology

inizio pagina